Washington, August 28 (ANI): Cedars-Sinai researchers have found that a common vitamin may have the potential to fight certain superbugs, antibiotic-resistant staph infections that health experts see as a threat to public health.
The research found that high doses of the nicotinamide form of vitamin B3 stimulated a specific gene (CEBPE), enhancing white blood cells' ability to combat staph infections, including methicillin-resistant Staphylococcus aureus or MRSA.
With research ongoing, including possible clinical trials in humans, the scientists caution consumers not to treat a suspected infection by taking vitamin B3. Instead, a physician should be consulted.
It's critical that we find novel antimicrobial approaches to treat infection and not rely so heavily on antibiotics, said George Liu, MD, PhD, a pediatric infectious disease physician at Cedars-Sinai's Maxine Dunitz Children's Health Center and co-senior author of the study.
That's why this discovery is so exciting. Our research indicates this common vitamin is potentially effective in fighting off and protecting against one of today's most concerning public health threats, he stated.
Staph infections commonly cause serious, sometimes life-threatening illness. Health officials fear that indiscriminate use of antibiotics has undercut their effectiveness, leading to the rapid rise and threatening spread of resistant germs.
In laboratory tests with mice and human blood, Cedars-Sinai scientists found that vitamin B3 increased by up to 1,000 fold the ability of the immune system to kill staph bacteria. Beyond its findings related to vitamin B3, the study indicates that similar targeting of the CEBPE gene with other compounds may offer a new immune-boosting strategy to fight bacterial infections.
The research has been published in the Journal of Clinical Investigation. (ANI)